Publications

Sars-Cov-2 Ba.5 Vaccine Breakthrough Risk and Severity Compared with Ba.2: a Case-Case and Cohort Study Using Electronic Health Records in Portugal

AuthID
P-019-NGG

Author(s)

Kislaya, I

Casaca, P

Borges, V

Sousa, C

Ferreira, BI

Fernandes, E

Dias, CM

Duarte, S

Almeida, JP

Grenho, I

[+6]·

Sobral, D

Nunes, A

Santos, D

Gonçalves, AM

Vieira, L

Gomes, JP

Leite, PP

Nunes, B

Machado, A

Peralta-Santos, A

View all authors

Document Type

Unpublished

Year published

2022

Published

Indexing

Crossref^®13

Google Scholar^®

Metadata
Sources

Publication Identifiers

DOI: 10.1101/2022.07.25.22277996

Export Publication Metadata

Marked List

Add to Marked List

Info

At this moment we don't have any links to full text documens.

All authors

Name Order	Name	Name Order	Name	Name Order	Name
1	Kislaya, I;	2	Casaca, P;	3	Borges, V;
4	Sousa, C;	5	Ferreira, BI;	6	Fernandes, E;
7	Dias, CM ;	8	Duarte, S;	9	Almeida, JP;
10	Grenho, I;	11	Coelho, L;	12	Ferreira, R;
13	Ferreira, PP;	14	Isidro, J;	15	Pinto, M;
16	Menezes, L;	17	Sobral, D;	18	Nunes, A;
19	Santos, D;	20	Gonçalves, AM;	21	Vieira, L;
22	Gomes, JP;	23	Leite, PP;	24	Nunes, B;
25	Machado, A;	26	Peralta-Santos, A;

Sars-Cov-2 Ba.5 Vaccine Breakthrough Risk and Severity Compared with Ba.2: a Case-Case and Cohort Study Using Electronic Health Records in Portugal

Useful Links

Get Help

Federated Authentication (Click on the image)

Sars-Cov-2 Ba.5 Vaccine Breakthrough Risk and Severity Compared with Ba.2: a Case-Case and Cohort Study Using Electronic Health Records in Portugal

Useful Links

Get Help